Loading...
XNASDYN
Market cap1.62bUSD
Jan 10, Last price  
15.87USD
1D
-31.15%
1Q
-52.87%
IPO
-29.78%
Name

Dyne Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:DYN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
42.03%
Rev. gr., 5y
%
Revenues
0k
3,103,000,0003,549,000,0002,468,000,0002,323,000,0001,585,000,0003,000,0003,000,0001,466,000,000842,000,0001,366,000,000506,000,000000000
Net income
-236m
L+42.79%
264,000,000174,000,000-1,262,000,000-234,000,000-1,645,000,00087,000,000-356,000,000-67,000,00050,000,000-1,240,000,00076,000,000-4,811,000-13,536,000-58,737,000-149,283,000-165,237,000-235,937,000
CFO
-188m
L+22.46%
341,000,000319,000,000135,000,000423,000,000-20,000,000-44,000,000175,000,000-62,000,00094,000,000676,000,000585,000,000-4,164,000-11,834,000-46,508,000-119,563,000-153,645,000-188,158,000
Earnings
Mar 03, 2025

Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
URL
https://www.dyne-tx.com/
IPO date
Sep 17, 2020
Employees
134
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
244,623
174,307
Unusual Expense (Income)
NOPBT
(244,623)
(174,307)
NOPBT Margin
Operating Taxes
(2,862)
Tax Rate
NOPAT
(244,623)
(171,445)
Net income
(235,937)
42.79%
(165,237)
10.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
52,369
36,861
BB yield
-6.60%
-6.12%
Debt
Debt current
9,440
4,610
Long-term debt
50,110
56,356
Deferred revenue
Other long-term liabilities
Net debt
(63,550)
(197,365)
Cash flow
Cash from operating activities
(188,158)
(153,645)
CAPEX
(729)
(3,067)
Cash from investing activities
83,311
87,202
Cash from financing activities
54,322
37,390
FCF
(239,603)
(168,897)
Balance
Cash
123,100
256,012
Long term investments
2,319
Excess cash
123,100
258,331
Stockholders' equity
(632,504)
(397,138)
Invested Capital
755,931
679,985
ROIC
ROCE
EV
Common stock shares outstanding
59,684
51,976
Price
13.30
14.75%
11.59
-2.52%
Market cap
793,795
31.77%
602,406
-0.45%
EV
730,245
405,041
EBITDA
(244,052)
(172,624)
EV/EBITDA
Interest
2,917
Interest/NOPBT